1
TRP53 INACTIVATION LEADS TO EARLIER PHEOCHROMOCYTOMA 1
FORMATION IN PTEN KNOCK-OUT MICE 2
1Esther Korpershoek,
2,3Nanne K. Kloosterhof,
1Angelique Ziel-van der Made,
1Hanneke 3
Korsten, 1Lindsey Oudijk,
1Jan Trapman,
1Winand N.M Dinjens, and
1Ronald R. de Krijger 4
5
1 Department of Pathology, and
2 Department of Neurology, Erasmus MC - University 6
Medical Centre Rotterdam, Josephine Nefkens Institute, The Netherlands 7
3 Department of Paediatric Oncology and Haematology, Erasmus Medical Centre-Sophia 8
Children’s Hospital, Rotterdam, The Netherlands 9
10
11
Short title = Malignant pheochromocytomas in KO mice 12
Keywords: Mouse model – pathogenesis – pheochromocytoma – Pten – Trp53 13
14
15
Corresponding Author: 16
Esther Korpershoek 17
Dept. of Pathology, Ae304 18
Erasmus MC, University Medical Centre Rotterdam 19
P.O. Box 2040 20
3000 CA Rotterdam 21
The Netherlands 22
Phone: +31-10-7038289 23
Fax: +31-10-7044762 24
Email: [email protected] 25
26
27
Page 1 of 29 Accepted Preprint first posted on 28 August 2012 as Manuscript ERC-12-0088
Copyright © 2012 by the Society for Endocrinology.
2
Abstract 1
Pheochromocytomas (PCC) are benign neuro-endocrine tumours of the adrenal medulla. 2
Approximately 10% of PCC patients develop metastases, but this frequency is much higher in 3
specific subtypes of patients. The reliable diagnosis of malignant PCC can only be made after 4
identification of a metastasis. To study the effect of Trp53 inactivation on PCC pathogenesis 5
in Pten KO mice, we investigated the adrenals of a large cohort of mice with conditional 6
monoallelic and biallelic inactivation of Trp53 and Pten. The adrenal weights were 7
determined for all mice, and in a proportion of these mice, immunohistochemistry for tyrosine 8
hydroxylase and dopamine beta-hydroxylase was performed on the adrenals and 9
corresponding lungs. Finally, comparative genomic hybridization (CGH) was performed. The 10
histological and immunohistochemical results confirmed that the adrenal tumours were PCC. 11
Inactivation of one or both alleles of Trp53 resulted in earlier tumour occurrence in the 12
PtenloxP/loxP
mice as well as in PtenloxP/+
mice. In addition, lung metastases were found in up to 13
67% of mice. The CGH results showed that the most frequent genomic alterations were loss 14
of chromosome 19 (86%) and gain of chromosome 15 (71%). In this study, we have shown 15
that Pten/Trp53 KO mice displayed metastatic PCC at high frequency and primary tumours 16
occurred at younger ages in mice with Trp53 inactivation. Therefore, the present model 17
appears to be a suitable model that might allow the preclinical study of new therapeutics for 18
these tumours. 19
20
21
Page 2 of 29
3
Introduction 1
In humans, pheochromocytomas (PCC) are relatively rare tumours that occur in the adrenal 2
medulla, and usually overproduce catecholamines, such as adrenalin or noradrenalin (Lenders, 3
et al. 2005). This overproduction causes high blood pressure, which in some cases may be 4
fatal, through myocardial infarction or stroke (Maher and Eng 2002). PCC occur sporadically 5
as well as in the context of hereditary syndromes, which include the multiple endocrine 6
neoplasia syndrome type 2, von Hippel-Lindau disease (VHL), neurofibromatosis type 1 7
(NF1), and the pheochromocytoma-paraganglioma (PCC-PGL) syndrome (Neumann, et al. 8
2002). The latter syndrome is characterized by both PCC and paragangliomas (PGL). PGL are 9
histologically similar to PCC, but are not always biochemically active. PGL can be 10
subdivided into parasympathetic PGL (pPGL) and sympathetic PGL (sPGL). pPGL occur in 11
the head-and-neck regions and usually do not produce catecholamines, whereas sPGL are 12
biochemically-active tumours that arise from chromaffin tissue outside the adrenal glands, 13
occurring in the thorax and abdomen along the neural crest (Neumann et al. 2002). 14
In addition to the genes described above, in the last decade other tumour suppressor genes 15
have been identified that were associated with PCC and/or PGL, such as SDHA, SDHAF2, 16
TMEM127, and MAX (Burnichon, et al. 2010; Comino-Mendez, et al. 2011; Hao, et al. 2009; 17
Qin, et al. 2010). Most PCC are benign, but approximately 10% of sporadic cases present 18
with metastases at diagnosis (Gimenez-Roqueplo, et al. 2006). This frequency can be much 19
higher, varying from 34 to 98%, in patients with a germline mutation in the succinate 20
dehydrogenase subunit B gene, although these numbers involve both PCC and sPGL (Amar, 21
et al. 2007; Benn, et al. 2006; Brouwers, et al. 2006; Neumann, et al. 2004; Timmers, et al. 22
2007). Currently, only one study has come up with a potentially interesting gene that could 23
differentiate metastatic and recurring pheochromocytomas from benign tumours. However, 24
the study was performed on a limited amount of pheochromocytomas, and it has not been 25
Page 3 of 29
4
validated in other series (Lee, et al. 2011). Besides this promising study, there are no 1
validated markers that can predict the malignant clinical behaviour of PCC in humans. 2
Currently, patients with metastatic PCC or PGL have few therapeutic options, which are all 3
on a palliative basis. Surgery is usually not curative for patients with metastases, but surgical 4
removal of the primary tumour and metastasis can prolong the patient’s life and improve life 5
quality. Radiotherapy with 131
I-MIBG is an option if patients have a good uptake of 123
I-6
MIBG in active metastases. In addition, systemic chemotherapy has also been used to treat 7
metastatic disease, however the numbers of patients in these studies were too small to draw 8
evidence-based conclusions (Adjalle, et al. 2009; Plouin, et al. 2012). A recent study on two 9
mouse PCC cell lines showed that a combination of drugs that specifically block mTORC1/2, 10
PI3K, ERK1/2, AKT, VEGF- and EGF-receptor function, can have a significant effect on the 11
growth of these tumour cells. These results could indicate a new therapeutic approach for 12
human malignant PCC (Nolting, et al. 2012). 13
There are many distinct knock-out mouse models that have been shown to develop 14
almost exclusively benign PCC (Korpershoek, et al. 2012). Genes that were silenced in these 15
models included Nf, Rb1, p130, p18(Ink4c), p27(Kip1), and Pten (Bai, et al. 2006; 16
Dannenberg, et al. 2004; Di Cristofano, et al. 2001; Franklin, et al. 2000; Nikitin, et al. 1999; 17
Powers, et al. 2000). Only two studies have reported mice with spontaneous development of 18
PCC lung metastases. These included the Pten KO mice of You et al., that displayed 19
metastases in a small percentage (15%) (You, et al. 2002), and our previous study in which 20
we reported a conditional Pten KO mouse model that also presented with lung metastasis, 21
which occurred in 35% of the mice of 10 months or older (Korpershoek, et al. 2009). 22
The PTEN gene is a tumour suppressor gene that is involved in the pathogenesis of 23
many tumour types, such as prostate and breast cancer, and belongs to the most frequently 24
mutated genes in human cancer. Although mouse models that involve the inactivation of the 25
Page 4 of 29
5
Pten gene develop PCC, human PCC have never been associated with PTEN mutations (van 1
Nederveen, et al. 2006). Nevertheless, the genomic alterations found in the PCC of Pten KO 2
mice show similarities with the genomic alterations found in human PCC, and loss of the 3
PTEN locus has also been reported in human PCC (Korpershoek et al. 2009; You et al. 2002). 4
Another gene that belongs to the most frequently mutated genes in human cancer is the 5
TP53 gene. TP53 has been associated with aggressiveness of tumour behaviour, including 6
local invasion and metastasis (Muller, et al. 2011). Although TP53 mutations have never been 7
found in human PCC, frequent loss of the TP53 genomic locus has been demonstrated in PCC 8
by loss of heterozygosity analysis and fluorescence in situ hybridization (Petri, et al. 2008). 9
The aggressive behaviour of TP53 mutated tumours is also illustrated in different mouse 10
models, in which metastatic lymphomas and osteosarcomas occur (Donehower, et al. 1992; 11
Jacks, et al. 1994). In addition, another study combined Rb with Trp53 to obtain a mouse 12
model with highly aggressive medulloblastomas (Marino, et al. 2000). 13
In the present study we have investigated the effect of inactivation of the Trp53 gene 14
(on a Cre-loxP basis, under the control of the PSA promoter) on the behaviour of PCC in 15
single or double Pten KO mice. Parameters investigated included the frequency of metastases, 16
the age of tumour presentation, size (weight) of the tumours, and chromosomal alterations. 17
18
Page 5 of 29
6
Materials and Methods 1
2
Generation of the Pten/Trp53 mice 3
Generation of the PtenloxP/loxP
and Trp53loxP/loxP
mice was described previously. (Ma, et al. 4
2005; Marino et al. 2000) The PtenloxP/loxP
animals were crossbred with the Trp53loxP/loxP
mice 5
to obtain PtenloxP/+
;Trp53loxP/+
offspring. This F1 offspring was inbred to obtain 6
PtenloxP/loxP
;Trp53loxP/loxP
mice, that were crossbred with the previously reported PSA-Cre+/- 7
mice (Ma et al. 2005). The PSA-Cre;PtenloxP/+
;Trp53loxP/+
offspring was interbred with 8
PtenloxP/loxP
;Trp53loxP/loxP
to obtain the six genotypes investigated. All mice used in this study 9
were male mice that carried the PSA-Cre construct, with the exception of the mice used as 10
healthy controls for the immunohistochemistry. 11
The current Pten/Trp53 KO mice were generated to obtain a mouse model with 12
prostate carcinomas that behave more aggressively, compared to the prostate tumors of the 13
Pten KO mouse model. These tumours will be described in a separate report (Korsten et al., 14
manuscript in preparation). Mice were housed according to institutional guidelines, and 15
procedures were carried out in compliance with the standards for use of laboratory animals. In 16
addition, animal experiments performed in this study have been approved by the animal 17
experimental committee of the Erasmus MC Medical Centre (DEC-consult). A total of 236 18
male mice of all genotypes were sacrificed at various pre-set ages, and all organs were 19
systematically investigated macroscopically and microscopically for abnormalities. Numbers 20
of mice per age group and genotype are displayed in Table 1. Alterations not related to PCC 21
or PCC metastases will be described in the additional report (Korsten et al, manuscript in 22
preparation). In addition, the weight of the adrenals was determined for all mice. Adrenal 23
glands that weighed 8 mg (twice the weight of a healthy adrenal) or more were considered as 24
tumour-containing. Mice were genotyped using tail DNA and PCR was performed with 25
Page 6 of 29
7
forward and reverse primers for Pten and Trp53 (primer sequences available on request). 1
Forty-eight adrenal tumours and 28 corresponding lungs of mice of different genotypes were 2
available for investigation. 3
4
Immunohistochemistry 5
Forty-eight formalin-fixed paraffin-embedded (FFPE) adrenals of 25 PSA-Cre;PtenloxP/loxP
, 8 6
PSA-Cre; PtenloxP/loxP
;Trp53loxP/+
, and 15 PSA-Cre; PtenloxP/loxP
;Trp53loxP/loxP
were 7
investigated with immunohistochemical markers according to the previously described 8
method with antibodies directed against tyrosine hydroxylase (TH) and dopamine-β-9
hydroxylase (DBH) (Korpershoek et al. 2009). In addition, immunohistochemistry with an 10
antibody for succinate dehydrogenase subunit B (Rabbit polyclonal HPA002686; Sigma-11
Aldrich, Saint Louis, MO, USA; 1/250) was performed according to procedures reported 12
previously (van Nederveen, et al. 2009). Furthermore, the 28 corresponding lungs were 13
histologically and immunohistochemically (TH and DBH) investigated for the presence of 14
PCC metastases. For each tumour and lung, negative controls were performed by omission of 15
the primary antibody. Lungs were systematically investigated for metastases by three step 16
sections of 5 µm at intervals of at least 10 µm. The adrenals of Cre-negative littermates were 17
used as positive controls. 18
19
Comparative Genomic Hybridization 20
Of the 14 mice of which snap-frozen PCC tissue was available, DNA was isolated using the 21
Gentra Puregene Tissue Kit (Qiagen, Venlo, The Netherlands) according to manufacturer’s 22
procedures. Labelling, hybridization conditions, and methods were described previously 23
(Korpershoek et al. 2009). For hybridization high-density whole-genome mouse bacterial 24
artificial chromosome microarray slides produced by the Central Microarray Facility of The 25
Page 7 of 29
8
Netherlands Cancer Institute in Amsterdam were used (Chung, et al. 2004). Slide scanning 1
was performed with the ScanArray Express HT (Perklin Elmer Life Science, Boston, MA). 2
Spot intensities were measured with GenePix Pro 5.1 software (Axon Instruments, Leusden, 3
The Netherlands). Excel 2000 and the aCGH-smooth application 4
(http://www.few.vu.nl/~vumarray/acgsmooth.htm) were used to analyze the normalized data. 5
The default settings of aCGH-smooth were used, except for λ = 8.5. The student’s t-test was 6
used to determine statistical differences between the genomic alterations found in the tumours 7
with and without Trp53 knock-down. 8
9
Page 8 of 29
9
Results 1
Trp53 inactivation leads to an earlier PCC presentation 2
All average tumour percentages and adrenal weights per age group and genotype are listed in 3
Tables 1 and 2, respectively. PCC occurred from the age of 11 months onwards in the 4
PtenloxP/loxP
and the PtenloxP/+
mice. In contrast, if one or two Trp53 alleles were inactivated in 5
the PtenloxP/loxP
mice, PCC occurred already at the age of 4 to 5 months. Both the 6
PtenloxP/loxP
;Trp53loxP/+
and the PtenloxP/loxP
;Trp53loxP/loxP
mice displayed a nearly full 7
penetrance at the age of 7-8 months (92% and 93% respectively). The main difference 8
between the two genotypes was that all PtenloxP/loxP
;Trp53loxP/loxP
mice had to be sacrificed at 9
the age of 8 months, because of severe health problems which could be related to the PCC or 10
prostate cancer, whereas the PtenloxP/loxP
;Trp53loxP/+
stayed healthy until the age of 15 months. 11
PtenloxP/+
mice showed the first PCC at 11-12 months, similar to the PtenloxP/loxP
, but at a 12
much lower frequency (33% versus 90%). In addition, monoallelic and biallelic inactivation 13
of Trp53 in the PtenloxP/-
did not result in an earlier tumour presentation. However, the 14
frequency of PCC occurrence was higher per age group compared to the PtenloxP/+
mice, 15
indicating the acceleration effect of Trp53 inactivation. 16
17
Immunohistochemistry 18
Forty-eight primary tumours were immunohistochemically stained for TH and DBH, to 19
confirm the tumours were PCC. All tumour cells stained positive for TH and DBH, as well as 20
the positive controls, which included the adrenals of Cre-negative mice. SDHB 21
immunohistochemistry was positive for all PCC investigated (Figure 1). 22
23
24
25
Page 9 of 29
10
Presence of lung metastases 1
In total, 28 lungs of mice with 3 different genotypes were available for investigation of the 2
presence of metastases (Table 3). Lungs were examined by histology and 3
immunohistochemistry with markers for TH and DBH. Metastases typically encompassed few 4
cells, usually approximately 5 to 10 cells with a maximum of 25 cells (illustrated in Figure 1). 5
Generally, up to 5 metastases were seen scattered throughout the lungs. PtenloxP/loxP
and 6
PtenloxP/loxP
;Trp53loxP/+
mice investigated displayed PCC metastases in 67% of mice (8 in 12 7
mice, and 2 in 3 mice, respectively). The PtenloxP/loxP
;Trp53loxP/loxP
showed lung metastases at 8
a similar frequency of 61.5% of mice (in 8 of 13 mice). 9
10
Comparative Genomic Hybridization 11
CGH was performed on 14 PCC of mice with four genotypes. An overview of the CGH 12
results is shown in Table 4 and a typical example is shown in Figure 2. 13
Overall, the most frequent chromosomal alterations were complete loss of chromosome 19 (in 14
85.7% of mice) and gain of (parts of) chromosome 15 (in 71.4% of mice). Furthermore, loss 15
of (parts of) chromosome 14 and chromosome 6 (in 42.9% and 35.7% of mice, respectively) 16
were demonstrated. 17
To investigate whether Trp53 inactivation influenced the occurrence of genomic 18
alterations, we split the mice in two groups. Group 1 included the recent PtenloxP/loxP
KO mice 19
(n = 4) and PtenloxP/loxP
KO mice (n = 8) of our previous study (Korpershoek et al. 2009), as 20
they are genotypically identical. Group 2 included the PtenloxP/+
;Trp53loxP/loxP
(n = 1), 21
PtenloxP/loxP
;Trp53loxP/+
(n = 7), and PtenloxP/loxP
;Trp53loxP/loxP
(n = 2) mice. The tumours of 22
group 1 displayed loss of chromosome 6 and 19 in 67% (8/12) mice, whereas tumours of 23
group 2 showed loss of chromosome 6 in 40% (4/10), and loss of chromosome 19 in 100% 24
(10/10). Gain of chromosome 15 was seen in 42% (5/12) of tumours of group 1, while 80% 25
Page 10 of 29
11
(8/10) of the tumours in group 2 showed gain of chromosome 15. The difference in frequency 1
of chromosomal alterations between the two groups was significant only for chromosome 15 2
(p = 0.046). 3
4
Page 11 of 29
12
Discussion 1
In this study, we have shown that the Pten/Trp53 KO mouse model presents metastatic PCC 2
at a high frequency, and that Trp53 inactivation leads to PCC, arising at similar frequencies, 3
but at earlier ages. In addition, monoallelic or biallelic Trp53 inactivation in Pten KO mice 4
does not lead to higher frequencies of metastases. The most frequently occurring genomic 5
alterations in PCC of mice with or without Trp53 knock-down involved the same 6
chromosomes. Although the frequencies of losses and gains were different between the two 7
groups, this difference was only significant in case of chromosome 15. 8
The PTEN gene belongs to the most frequently mutated genes in human cancer. The 9
main function of PTEN is to convert phosphatidylinositol (3,4,5)-triphosphate to 10
phosphatidylinositol (4,5)-diphosphate, thereby inhibiting the activation of AKT and its 11
down-stream targets (Di Cristofano and Pandolfi 2000). Although PTEN mutations have not 12
been found in human pheochromocytomas, overexpression of its downstream target AKT, has 13
been associated with human pheochromocytomas (Fassnacht, et al. 2005). To investigate the 14
effect of PTEN inactivation in tumorigenesis, many Pten KO mouse models have been 15
generated (Di Cristofano et al. 2001; Freeman, et al. 2006; Korpershoek et al. 2009; Lesche, 16
et al. 2002; Ma et al. 2005; Podsypanina, et al. 1999; Suzuki, et al. 1998; You et al. 2002). In 17
the conventional Pten KO mouse models, Pten nullizygosity leads to embryonic lethality, 18
whereas Pten heterozygotes present with many different tumours, mainly prostate cancer and 19
often pheochromocytomas (Suzuki et al. 1998; You et al. 2002). To investigate the exact 20
effect of PTEN inactivation in the prostate, a prostate-specific conditional mouse model was 21
generated using the Cre-lox system under the control of the PSA-promoter (Ma et al. 2005). 22
The PtenloxP/loxP
KO mice developed invasive prostate carcinomas and metastatic 23
pheochromocytomas, of which the earliest pheochromocytomas occurred in mice aged 7 to 9 24
months. In the present study, the PtenloxP/loxP
mice again presented metastatic PCC at similar 25
Page 12 of 29
13
frequencies as the mice of the previous study (Korpershoek et al. 2009). In addition, PCC 1
lung tumours were confirmed to be TH and DBH immunohistochemistry, as these markers are 2
normally not present in cells of the lungs. 3
TP53 is the most frequently mutated gene in human cancer. It acts as a tumour 4
suppressor gene and regulates different cellular functions, including cellular senescence and 5
apoptosis. In a healthy cell, p53 is suppressed by E3 ubiquitin ligase MDM2 (mouse double 6
minute 2), which will bind to p53 and ubiquinate p53 for degradation (Muller et al. 2011; 7
Nigro, et al. 1989). In a stressed cell p53 will be activated, promoting cell-cycle arrest or 8
apoptosis. Recently, mutated TP53 has been associated with cell migration and invasion, 9
suggesting that p53 inactivation can contribute to a tumour’s metastatic potential (Muller et 10
al. 2011). In the present study, the monoallelic and biallelic inactivation of Trp53 resulted in 11
an earlier tumour presentation in the Pten KO mice. In addition, PCC lung metastases also 12
occurred at younger ages, but without an increased frequency compared to that in mice with 13
solely Pten inactivation. It must be noted that numbers were too small to perform statistical 14
analysis. No TP53 mutations have been found in human pheochromocytomas, although 15
chromosomal loss of the TP53 gene has been demonstrated. However, there appeared to be no 16
difference in frequencies between benign or malignant tumours (Petri et al. 2008). 17
Genetic alterations have been investigated by comparative genomic hybridization 18
(CGH) in 2 Pten KO mouse models (Korpershoek et al. 2009; You et al. 2002). The first 19
study investigated the PCC of (conventional) heterozygous KO mice and found loss of 20
chromosome 4 as the most frequent genetic alteration (You et al. 2002). In contrast, in our 21
previous study, we found almost no loss of chromosome 4 in our (conditional) Pten KO mice, 22
but found loss of chromosome 6 and 19 as the main chromosomal alterations (Korpershoek et 23
al. 2009). In the present study, we performed CGH on 14 PCC of 4 different genotypes. The 24
most frequent aberration found was loss of chromosome 19 and gain of chromosome 15. The 25
Page 13 of 29
14
frequency of loss of chromosome 19 was similar to that of the previous study (86% and 75% 1
respectively). 2
To determine what the effect of Trp53 inactivation was on the chromosomal 3
alterations, the mice were split into two groups. Group 1 included the mice PtenloxP/loxP
mice 4
of the present and previous study (as they are genotypically identical) (Korpershoek et al. 5
2009), and group 2 included PtenloxP/+
;Trp53loxP/loxP
, PtenloxP/loxP
;Trp53loxP/+
, and 6
PtenloxP/loxP
;Trp53loxP/loxP
mice. Inactivation of Trp53 did not result in changes other than 7
minor frequency differences in chromosomal alterations. Loss of chromosome 6 occurred in 8
40% of the group 1 tumours and in 67% of the group 2 tumours. In addition, all group 2 9
tumours showed loss of chromosome 19, whereas group 1 tumours showed loss in 67%. 10
Finally, the group 2 tumours displayed gain of chromosome 15 in 80% of cases, whereas the 11
group 1 tumours showed gain in 40%. Gain of chromosome 15 was the only significant 12
difference between the two groups. Notably, no loss of the Trp53 wild type allele was seen in 13
tumours of PtenloxP/loxP
;Trp53loxP/+
mice, indicating that loss of one Trp53 allele is sufficient 14
to accelerate PCC pathogenesis in these mice. 15
Mouse chromosome 19 includes a region that is syntenic to human chromosome 16
11q13, which is associated with SDHD-related and VHL-related PCC, indicating involvement 17
of this chromosomal area in the pathogenesis of these tumours. Mouse chromosome 15 is 18
syntenic to human chromosome 5p13-15, of which 5p has been associated with the 19
pathogenesis of human malignant PCC (personal observations of a large series of human 20
malignant PCC). This shows that these mice PCC have genetic aberrations that could provide 21
clues about chromosomal areas containing genes involved in human PCC. However, these 22
areas include too many genes to predict which genes could be of importance. 23
In SDHB-related human PCC the frequency of metastases is relatively high (34-98%) 24
compared to sporadic PCC (Amar et al. 2007; Gimenez-Roqueplo et al. 2006; Neumann et al. 25
Page 14 of 29
15
2004; Timmers et al. 2007). In the present study, we performed SDHB immunohistochemistry 1
on the PCC of the Pten and Trp53 KO mice, and found only tumours with positive tumour 2
cells indicating there are no SDH mutations present (van Nederveen et al. 2009). Therefore, it 3
is highly unlikely that succinate dehydrogenase (mitochondrial complex II) is involved in the 4
pathogenesis of these mouse tumours. This is in accordance with our previous findings, as 5
Sdhb or Sdhd mutations were not found in the PtenloxP/loxP
mice (Korpershoek et al. 2009). 6
In conclusion, we have investigated a large cohort mouse adrenal glands from six 7
different genotypes showing that tumours occurred at much earlier ages in the 8
PtenloxP/loxP
;Trp53loxP/loxP
and the PtenloxP/lox
;Trp53loxP/+
mice, compared to the PtenloxP/loxP
9
mice, indicating the accelerating effect of Trp53 inactivation on pathogenesis of these 10
tumours. Although Trp53 inactivation leads to earlier PCC occurrence, it does not result in 11
higher frequencies of metastases. 12
13
Page 15 of 29
16
Declaration of interest 1
The authors declare to have no conflict of interest. 2
3
Author contributions 4
EK, RRdK, WNMD, and JT were involved in study design and data interpretation. EK, NKF, 5
AZvdM, HK, and LO collected the samples and carried out the experiments. EK and NKF 6
analysed the data. All authors were involved in writing the paper and had final approval of the 7
submitted and published versions. 8
9
10
11
Page 16 of 29
17
References 1
Adjalle R, Plouin PF, Pacak K & Lehnert H 2009 Treatment of malignant 2
pheochromocytoma. Horm Metab Res 41 687-696. 3
Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, Bertagna X, Schlumberger 4
M, Jeunemaitre X, Gimenez-Roqueplo AP, et al. 2007 Succinate dehydrogenase B gene 5
mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. 6
J Clin Endocrinol Metab 92 3822-3828. 7
Bai F, Pei XH, Pandolfi PP & Xiong Y 2006 p18 Ink4c and Pten constrain a positive 8
regulatory loop between cell growth and cell cycle control. Mol Cell Biol 26 4564-4576. 9
Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, 10
Dahia PL, Elston M, Gimm O, et al. 2006 Clinical presentation and penetrance of 11
pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 91 827-836. 12
Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM & Pacak K 2006 13
High frequency of SDHB germline mutations in patients with malignant catecholamine-14
producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 91 15
4505-4509. 16
Burnichon N, Briere JJ, Libe R, Vescovo L, Riviere J, Tissier F, Jouanno E, Jeunemaitre X, 17
Benit P, Tzagoloff A, et al. 2010 SDHA is a tumor suppressor gene causing paraganglioma. 18
Hum Mol Genet 19 3011-3020. 19
Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, Landa I, Leandro-Garcia LJ, Leton R, 20
Honrado E, Ramos-Medina R, Caronia D, Pita G, et al. 2011 Exome sequencing identifies 21
MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 43 663-667. 22
Chung YJ, Jonkers J, Kitson H, Fiegler H, Humphray S, Scott C, Hunt S, Yu Y, Nishijima I, 23
Velds A, et al. 2004 A whole-genome mouse BAC microarray with 1-Mb resolution for 24
Page 17 of 29
18
analysis of DNA copy number changes by array comparative genomic hybridization. Genome 1
Res 14 188-196. 2
Dannenberg JH, Schuijff L, Dekker M, van der Valk M & te Riele H 2004 Tissue-specific 3
tumor suppressor activity of retinoblastoma gene homologs p107 and p130. Genes Dev 18 4
2952-2962. 5
Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C & Pandolfi PP 2001 Pten and 6
p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27 222-224. 7
Di Cristofano A & Pandolfi PP 2000 The multiple roles of PTEN in tumor suppression. Cell 8
100 387-390. 9
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr., Butel JS & 10
Bradley A 1992 Mice deficient for p53 are developmentally normal but susceptible to 11
spontaneous tumours. Nature 356 215-221. 12
Fassnacht M, Weismann D, Ebert S, Adam P, Zink M, Beuschlein F, Hahner S & Allolio B 13
2005 AKT is highly phosphorylated in pheochromocytomas but not in benign adrenocortical 14
tumors. J Clin Endocrinol Metab 90 4366-4370. 15
Franklin DS, Godfrey VL, O'Brien DA, Deng C & Xiong Y 2000 Functional collaboration 16
between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct 17
tissue specificity. Mol Cell Biol 20 6147-6158. 18
Freeman D, Lesche R, Kertesz N, Wang S, Li G, Gao J, Groszer M, Martinez-Diaz H, 19
Rozengurt N, Thomas G, et al. 2006 Genetic background controls tumor development in 20
PTEN-deficient mice. Cancer Res 66 6492-6496. 21
Gimenez-Roqueplo AP, Lehnert H, Mannelli M, Neumann H, Opocher G, Maher ER & 22
Plouin PF 2006 Phaeochromocytoma, new genes and screening strategies. Clin Endocrinol 23
(Oxf) 65 699-705. 24
Page 18 of 29
19
Hao HX, Khalimonchuk O, Schraders M, Dephoure N, Bayley JP, Kunst H, Devilee P, 1
Cremers CW, Schiffman JD, Bentz BG, et al. 2009 SDH5, a gene required for flavination of 2
succinate dehydrogenase, is mutated in paraganglioma. Science 325 1139-1142. 3
Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT & Weinberg RA 4
1994 Tumor spectrum analysis in p53-mutant mice. Curr Biol 4 1-7. 5
Korpershoek E, Loonen AJ, Corvers S, van Nederveen FH, Jonkers J, Ma X, Ziel-van der 6
Made A, Korsten H, Trapman J, Dinjens WN, et al. 2009 Conditional Pten knock-out mice: a 7
model for metastatic phaeochromocytoma. J Pathol 217 597-604. 8
Korpershoek E, Pacak K & Martiniova L 2012 Murine Models and Cell Lines for the 9
Investigation of Pheochromocytoma: Applications for Future Therapies? Endocr Pathol. 10
Lee TK, Murthy SR, Cawley NX, Dhanvantari S, Hewitt SM, Lou H, Lau T, Ma S, Huynh T, 11
Wesley RA, et al. 2011 An N-terminal truncated carboxypeptidase E splice isoform induces 12
tumor growth and is a biomarker for predicting future metastasis in human cancers. J Clin 13
Invest 121 880-892. 14
Lenders JW, Eisenhofer G, Mannelli M & Pacak K 2005 Phaeochromocytoma. Lancet 366 15
665-675. 16
Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, Liu X & Wu H 2002 Cre/loxP-17
mediated inactivation of the murine Pten tumor suppressor gene. Genesis 32 148-149. 18
Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, van Duijn P, 19
Cleutjens KB, de Krijger R, Krimpenfort P, Berns A, et al. 2005 Targeted biallelic 20
inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased 21
epithelial cell proliferation but not by reduced apoptosis. Cancer Res 65 5730-5739. 22
Maher ER & Eng C 2002 The pressure rises: update on the genetics of phaeochromocytoma. 23
Hum Mol Genet 11 2347-2354. 24
Page 19 of 29
20
Marino S, Vooijs M, van Der Gulden H, Jonkers J & Berns A 2000 Induction of 1
medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external 2
granular layer cells of the cerebellum. Genes Dev 14 994-1004. 3
Muller PA, Vousden KH & Norman JC 2011 p53 and its mutants in tumor cell migration and 4
invasion. J Cell Biol 192 209-218. 5
Neumann HP, Hoegerle S, Manz T, Brenner K & Iliopoulos O 2002 How many pathways to 6
pheochromocytoma? Semin Nephrol 22 89-99. 7
Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, 8
Franke G, Klisch J, Bley TA, et al. 2004 Distinct clinical features of paraganglioma 9
syndromes associated with SDHB and SDHD gene mutations. JAMA 292 943-951. 10
Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson 11
N, Baylin S, Devilee P, et al. 1989 Mutations in the p53 gene occur in diverse human tumour 12
types. Nature 342 705-708. 13
Nikitin AY, Juarez-Perez MI, Li S, Huang L & Lee WH 1999 RB-mediated suppression of 14
spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/- mice. Proc Natl 15
Acad Sci U S A 96 3916-3921. 16
Nolting S, Garcia E, Alusi G, Giubellino A, Pacak K, Korbonits M & Grossman AB 2012 17
Combined blockade of signalling pathways shows marked anti-tumour potential in 18
phaeochromocytoma cell lines. J Mol Endocrinol 49 79-96. 19
Petri BJ, Speel EJ, Korpershoek E, Claessen SM, van Nederveen FH, Giesen V, Dannenberg 20
H, van der Harst E, Dinjens WN & de Krijger RR 2008 Frequent loss of 17p, but no p53 21
mutations or protein overexpression in benign and malignant pheochromocytomas. Mod 22
Pathol 21 407-413. 23
Page 20 of 29
21
Plouin PF, Fitzgerald P, Rich T, Ayala-Ramirez M, Perrier ND, Baudin E & Jimenez C 2012 1
Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Horm Metab Res 2
44 390-399. 3
Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, 4
Catoretti G, Fisher PE & Parsons R 1999 Mutation of Pten/Mmac1 in mice causes neoplasia 5
in multiple organ systems. Proc Natl Acad Sci U S A 96 1563-1568. 6
Powers JF, Evinger MJ, Tsokas P, Bedri S, Alroy J, Shahsavari M & Tischler AS 2000 7
Pheochromocytoma cell lines from heterozygous neurofibromatosis knockout mice. Cell 8
Tissue Res 302 309-320. 9
Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, Lechleiter JD, Sass M, 10
Aronin N, Schiavi F, et al. 2010 Germline mutations in TMEM127 confer susceptibility to 11
pheochromocytoma. Nat Genet 42 229-233. 12
Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, 13
Wakeham A, Itie A, Khoo W, et al. 1998 High cancer susceptibility and embryonic lethality 14
associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 8 1169-1178. 15
Timmers HJ, Kozupa A, Eisenhofer G, Raygada M, Adams KT, Solis D, Lenders JW & 16
Pacak K 2007 Clinical presentations, biochemical phenotypes, and genotype-phenotype 17
correlations in patients with succinate dehydrogenase subunit B-associated 18
pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 92 779-786. 19
van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, Sleddens 20
HF, Derkx P, Riviere J, Dannenberg H, et al. 2009 An immunohistochemical procedure to 21
detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or 22
SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 10 764-771. 23
Page 21 of 29
22
van Nederveen FH, Perren A, Dannenberg H, Petri BJ, Dinjens WN, Komminoth P & de 1
Krijger RR 2006 PTEN gene loss, but not mutation, in benign and malignant 2
phaeochromocytomas. J Pathol 209 274-280. 3
You MJ, Castrillon DH, Bastian BC, O'Hagan RC, Bosenberg MW, Parsons R, Chin L & 4
DePinho RA 2002 Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of 5
tumorigenesis in mice. Proc Natl Acad Sci U S A 99 1455-1460. 6
7
8
9
Page 22 of 29
23
Figure Legends 1
2
Figure 1. 3
Haematoxylin eosin staining of normal adrenal (A), pheochromocytomas (C), and lung 4
metastasis (D); TH immunohistochemistry of normal adrenal (B) and lung metastasis (E); and 5
SDHB immunohistochemistry of pheochromocytoma (F). 6
7
Figure 2. 8
Example of a CGH result of mouse chromosome 6, displaying gain of chromosome 2, loss of 9
whole chromosome 6 and 14, and a part of chromosome 7. 10
11
12
13
Page 23 of 29
Table 1. Presentation of PCC in mice of different ages and different genotypes
Genotype 2 months 4-5 months 7-8 months 11-12 months 15 months 18 months
PtenloxP/loxP 0 / 7 0 / 10 0 / 9 9 / 10 (90%) 7 / 7 (100%) -
PtenloxP/loxP;Trp53loxP/+ 0 / 2 1 / 10 (10%) 11 / 12 (92%) 12 / 12 (100%) 8 / 8 (100%) -
PtenloxP/loxP;Trp53loxP/loxP 0 / 7 2 / 10 (20%) 27 / 29 (93%) - - -
PtenloxP/+ 0 / 2 0 / 11 0 / 10 2 / 8 (25%) 1 / 4 (25%) 3 / 5 (60%)
PtenloxP/+;Trp53loxP/+ 0 / 2 0 / 7 0 / 5 2 / 6 (33%) 3 / 3 (100%) 3 / 3 (100%)
PtenloxP/+;Trp53loxP/loxP 0 / 3 0 / 10 0 / 9 7 / 9 (78%) 5 / 5 (100%) -
Total 0 / 23 2 / 58 (3.4%) 38 / 75 (51%) 32 / 45 (71%) 24 / 27 (89%) 6 / 8 (75%)
The columns contain the number of mice presenting with PCC per total numbers of mice, and the corresponding percentages are between
brackets. Above the columns are the different age groups at the time of sacrifice.
Page 24 of 29
Table 2. Adrenal weights at different ages per different genotype.
Genotype 2
months
SD
4-5
months
SD
7-8
months
SD
11-12
months
SD
15
months
SD
18
months
SD
PtenloxP/loxP
3.8 mg 1.1 5.0 mg 1.1 5.0 mg 1.3 44.0 mg 50.0 122 mg 93.5 -
PtenloxP/loxP;Trp53loxP/+ 6.3 mg 0.9 5.9 mg 3.6 17.5 mg 11.1 225 mg 183 326 mg 209 -
PtenloxP/loxP;Trp53loxP/loxP 3.7 mg 1.4 8.6 mg 9.2 38.0 mg 99.3 - - -
PtenloxP/+
4.0 mg 1.3 3.5 mg 0.6 2.8 mg 0.7 6.0 mg 4 72.7 mg 142 26.8 mg 44.4
PtenloxP/+
;Trp53loxP/+
3.8 mg 1.2 3.5 mg 1.4 3.3 mg 1.7 158 mg 377 210 mg 310 338 mg 286
PtenloxP/+;Trp53loxP/loxP 3.6 mg 0.9 3.0 mg 1.1 3.6 mg 1.0 72.7 mg 117 163 mg 126 -
Page 25 of 29
Table 3. Presence of PCC lung metastases
Mouse # adrenal weight (mg) age (months) lung metastasis present
PtenloxP/loxP 1 32 10 Y
2 41.4 12 N
3 20.5 12 Y
4 133 12 Y
5 32.1 12 Y
6 140 12 Y
7 9.6 12 N
8 26.2 15 N
9 66.4 15 Y
10 103 15 Y
11 80.3 15 Y
12 69.7 15 N
PtenloxP/loxP
;Trp53loxP/+
13 286 11 Y
14 117 12 Y
15 71 15 N
PtenloxP/loxP;Trp53loxP/loxP 16 40.5 7 Y
17 8.0 7 N
18 21.8 7 Y
19 27.5 8 Y
20 33.7 8 N
21 18.0 8 N
22 27.3 8 Y
23 18.1 8 N
24 46.8 8 Y
25 38.2 8 Y
26 15.1 8 Y
27 34.8 8 Y
28 55.6 11 N
Page 26 of 29
Table 4. Overview of CGH results
Mouse # Genotype Chr. 2 Chr. 4 Chr. 6 Chr. 7 Chr. 8 Chr. 9 Chr. 13 Chr. 14 Chr. 15 Chr. 16 Chr. 19
3 PtenloxP/loxP
WC - 62-103Mb +
4 PtenloxP/loxP
WC + WC -
6 PtenloxP/loxP 42-181Mb + 27-150Mb - 79-153Mb - WC -
10 PtenloxP/loxP
WC - 51-153MB - WC -
13 PtenloxP/loxP
;Trp53loxP/+
WC - WC + WC -
14 PtenloxP/loxP
;Trp53loxP/+
WC + WC -
15 PtenloxP/loxP
;Trp53loxP/+
30-61Mb + 88-103Mb + WC -
30 PtenloxP/loxP;Trp53loxP/+ WC + WC -
31 PtenloxP/loxP
;Trp53loxP/+
112-153Mb - WC + WC -
32 PtenloxP/loxP
;Trp53loxP/+
WC + WC - WC + WC + WC -
33 PtenloxP/loxP;Trp53loxP/+ WC+ WC -
18 PtenloxP/loxP
;Trp53loxP/loxP
WC - 100-153Mb - WC - WC - 0-104Mb - WC -
28 PtenloxP/loxP
;Trp53loxP/loxP
WC - WC + WC -
29 PtenloxP/+
;Trp53loxP/loxP
0-18Mb - WC - WC - WC - WC -
This table shows an overview of the genomic alterations found in 14 mouse PCC. WC = whole chromosome, - = loss, + = gain. Some losses or
gains are parts of chromosomes, than megabases are shown.
Page 27 of 29
Top Related